Skip to main content

Table 3 Associations with time to major adverse cardiovascular events and all-cause mortality

From: Multimorbidity, polypharmacy, and drug-drug-gene interactions following a non-ST elevation acute coronary syndrome: analysis of a multicentre observational study

 

MACE

ACM

HR (95% CI)

p value

HR (95% CI)

p value

Univariate analysis

 Sex (F vs M)

1.49 (1.02–2.18)

0.038

1.40 (0.88–2.24)

0.16

 Age

1.05 (1.04–1.07)

2.0 × 10−9

1.09 (1.06–1.11)

1.9 × 10−12

 All multimorbidity

2.69 (1.73–4.20)

1.2 × 10−5

2.75 (1.56–4.84)

4.8 × 10−4

 Number of drugs

1.15 (1.10–1.21)

2.0 × 10−8

1.14 (1.08–1.21)

3.0 × 10−6

 Number of all interactions

1.16 (0.995–1.34)

0.058

1.01 (0.83–1.23)

0.93

 Number of substantial interactions

1.23 (0.997–1.51)

0.053

1.11 (0.84–1.46)

0.47

Multivariable analysis

 Age

1.05 (1.03–1.07)

8.9 × 10−7

1.08 (1.06–1.11)

1.9 × 10−12

 All multimorbidity

1.76 (1.10–2.82)

0.019

–

–

 Number of drugs

1.10 (1.04–1.16)

1.2 × 10−3

1.12 (1.05–1.19)

4.0 × 10−4

  1. ACM all-cause mortality, CI confidence interval, HR hazard ratio, MACE major adverse cardiovascular events
  2. All types of interaction (drug-drug, drug-gene, drug-drug-gene, and drug-gene-gene) were counted to determine numbers of all and numbers of predicted substantial interactions per patient